Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Enzyme inhibitor
Emricasan
Другие языки:

    Emricasan

    Подписчиков: 0, рейтинг: 0
    Emricasan
    Emricasan structure.png
    Legal status
    Legal status
    Identifiers
    • (3S)-3-{[(2S)-2-{[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C26H27F4N3O7
    Molar mass 569.501 g·mol−1
    3D model (JSmol)
    • C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C
    • InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
    • Key:SCVHJVCATBPIHN-SJCJKPOMSA-N

    Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010. Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization.

    The substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects. It was developed for the treatment of liver disease and has been granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis cirrhosis The substance is the first pan-caspase inhibitor to advance to broad clinical testing, and its novel mechanism of action has led to research using it for other potential applications.


    Новое сообщение